



# Silva Pharmaceuticals Limited

সিলভা ফার্মাসিউটিক্যালস লিমিটেড

Ref: SPL/SD/2025/144

Date: November 13, 2025

## The Chairman

Bangladesh Securities and Exchange Commission (BSEC),  
Securities Commission Bhaban, E-6/C, Agargaon,  
Sher-e-Bangla Nagar Administrative Area,  
Dhaka-1207, Bangladesh.

## Subject: Revised Price Sensitive Information (PSI) for holding the Extraordinary General Meeting (EGM).

Dear Sir,

In compliance of the Bangladesh Securities and Exchange Commission Gazette order No. SEC/CMRRCD/2009-193/179/ADMIN/64 dated 07/12/2015, we hereby inform you that the Board of Directors of Silva Pharmaceuticals Limited (the "Company") in its meeting held on **November 13, 2025, at 3:30 PM**, has taken the following decisions, which are subject to approval by the shareholders at the upcoming **9th Extraordinary General Meeting (EGM)** and the Bangladesh Securities and Exchange Commission (BSEC):

### 1. Change of Company Name and Amend the Articles of Association:

Change the registered name of the Company from "**Silva Pharmaceuticals Limited**" to "**Silva Pharmaceuticals PLC**" in accordance with the Companies Act, 1994 (amended in 2020), and amend the relevant clauses of the Memorandum and Articles of Association of the Company accordingly.

Additionally, the specific amendment to Clause 86 of the Articles of Association to streamline the composition of the Board. The proposed changes are given below:

#### PROPOSED AMENDMENT TO CLAUSE 86:

Current Wording	Proposed Wording
"In General Meeting the number of the members shall not be less than 5 (Five). For Board Meetings the Quorum shall be 5 (Five) members of Board of Directors.	"In General Meeting the number of the members shall not be less than 5 (Five). For Board Meetings the Quorum shall be 3 (Three) members of Board of Directors.
I. The Directors representing sponsor shareholders shall be elected by the existing sponsor Directors or by their nominee. II. At least Three (3) Directors shall be elected among the sponsor shareholders. III. In future the successors of the Director or their legal nominees will be eligible to become Director as per law."	I. The Directors representing sponsor shareholders shall be elected by the existing sponsor Directors or by their nominee. II. In future the successors of the Director or their legal nominees will be eligible to become Director as per law."

### 2. Post-Facto Approval of Project Revisions:

The Board granted post-facto approval for the following changes in the design, drawing, and construction of the new factory building, as well as the procurement of machinery and equipment, which deviated from the original plan outlined in the prospectus:

#### o **Factory Design and Structure:**

The factory design was revised from a two-storied civil construction to a pre-fabricated steel structure, with the total built-up area expanded to **45,848.02 square feet**, compared to the originally proposed **20,000 square feet**.

#### o **Machinery and Equipment:**

To achieve full compliance with mandatory cGMP and DGDA guidelines, the company procured and installed certain additional machinery and equipment that were not included in the original prospectus. These upgrades were essential to meet updated regulatory requirements and enhance production efficiency, ensuring that all pharmaceutical products **adhere to the highest levels of quality and safety**.

#### Corporate & Registered Office:

House # 65, Road # 8/A (New)  
Dhanmondi, Dhaka-1209, Bangladesh  
Phone: +880-2-9146009, 8191336  
Fax: +880-2-9146013  
Email: info@silvapharma.com  
Web: www.silvapharma.com



#### Factory:

Main Road, Majidee Court  
Noakhali, Bangladesh  
Phone: +880-321-63301  
Fax: +880-321-63303  
Email: factory@silvapharma.com



## Silva Pharmaceuticals Limited

সিলভা ফার্মাসিউটিক্যালস্ লিমিটেড

### 3. Revised proposal for utilization of IPO Proceeds:

In view of the strategic objective of the company and to meet its immediate financial obligations and operating exigencies, the board of directors of the company has considered the **revised proposal for utilization of IPO proceeds** in the following:

#### A. Post-Facto Approval:

Ratified the utilization of accrued profit from IPO proceeds totaling **BDT 90,30,327.00 (Ninety Lakh Thirty Thousand Three Hundred Twenty-Seven Taka Only)**, comprising:

- BDT 24,74,124.00 for civil construction of the new factory building; and
- BDT 65,56,203.00 for working capital purposes.

#### B. Approval for Working Capital Utilization:

The utilization of a total sum of **BDT 5,00,00,000.00 (Five Crore Taka Only)** for the Company's working capital requirements, to be sourced from:

- The unutilized IPO principal amounting **BDT 2,81,82,638.00**, currently retained under the head of **Machinery & Equipment**; and
- The remaining accrued profit of **BDT 2,18,17,362.00**, together with any additional profit accrued up to the date of fund redemption.

### Details of the 9th Extraordinary General Meeting (EGM):

- **Date of EGM:** Tuesday, December 30, 2025
- **Time:** 10:30 AM
- **Mode & Venue:** Hybrid System (both Physical Presence and Digital Platform). *The physical venue will be notified subsequently.*
- **Record Date:** Thursday, December 04, 2025.\*

**\*Please note that due to a printing error, the previously published PSI incorrectly stated the Record Date as Monday, December 01, 2025.**


#### Notes:

1. Trading of the company's securities will remain suspended on the Record Date. Shareholders whose names appear in the Register of Members or with the depository as of the Record Date will be eligible to attend and vote at the EGM.
2. Members are requested to update their contact details (address, phone, email) through their respective Depository Participants (DP) before the record date.
3. In accordance with BSEC Circular No. SEC/CMRRCD/2009-193/154 dated October 24, 2013, no food or gifts will be provided at the EGM.

This is submitted for your kind information and records.

Thank you.

Sincerely,

  
**Md. Jabbar Hossain**  
Company Secretary  
Silva Pharmaceuticals Limited

Copy to:

1) **Managing Director**  
**Dhaka Stock Exchange PLC,**  
DSE Tower, Plot # 46,  
Road # 21, Nikunja-2, Dhaka-  
1229, Bangladesh

2) **Managing Director**  
**Chittagong Stock Exchange**  
**PLC,**  
52-53, *Dilkusha C/A, (level-15),*  
Dhaka-1000, Bangladesh

3) **Managing Director & CEO**  
**Central Depository Bangladesh**  
**Ltd.**  
Level-5, DSE Tower, House-46  
Road No. 21, Dhaka-1229,  
Bangladesh

Corporate & Registered Office:  
House # 65, Road # 8/A (New)  
Dhanmondi, Dhaka-1209, Bangladesh  
Phone: +880-2-9146009, 8191336  
Fax: +880-2-9146013  
Email: info@silvapharma.com  
Web: www.silvapharma.com

**Factory:**  
Main Road, Majidee Court  
Noakhali, Bangladesh  
Phone: +880-321-63301  
Fax: +880-321-63303  
Email: factory@silvapharma.com